In a randomized trial, adults who continued semaglutide kept losing weight over the following 48 weeks, averaging a further 7.9 percent reduction, while those switched to placebo regained about 6.9 percent, according to the STEP 4 randomized clinical trial in JAMA, 2021
If these persist or worsen, contact your healthcare provider
Food and Drug Administration (FDA) is the primary regulatory body in the United States responsible for ensuring the safety, efficacy, and quality of medical products
For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk
Eat Low-Fat, Small Meals Fat is the hardest macronutrient for your GI tract to process during GLP-1 therapy